# Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

> **NCT02485535** · PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- de Novo Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT02485535
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-04
- **Primary completion:** 2018-02-28
- **Final completion:** 2020-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485535, "Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02485535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*